When Lorna De Leoz invited laboratories to participate in her glycomics study, she hoped for 20 responses. Instead, she was deluged by emails from around the world.
De Leoz, at the time a research chemist at the National Institute for Standards and Technology, or NIST, was planning a study on how pharmaceutical and academic laboratories measure glycans, complex carbohydrate molecules that cells use to post-translationally modify various proteins. The project, the subject of a paper in this month's issue of Molecular & Cellular Proteomics , grew to include 76 participating labs.
The flood of responses, including from many well-known pharmaceutical companies, illustrates the industry's appetite for a better understanding of protein glycosylation. A growing number of drugs are made from proteins -- most often antibodies -- and this is a big variable in manufacturing them.
Glycans make up no more than 3% of the weight of an antibody-based drug, but they have an outsized impact. A change in glycosylation from one batch to the next can alter a drug's binding to its target or the likelihood that it will be attacked by the patient's immune system. To make sure patients receive the safest and most effective medicine, researchers must be able to keep track of the glycosylation status of antibody drugs.
Stephen Stein, a fellow at NIST's mass spectrometry data center, was the senior author of the study. "Glycosylation is one of the most important physical-chemical aspects of biology," he said, "but one of the most difficult to analyze."
Glycans' complex and heterogeneous structures make analysis difficult. Unlike macromolecules such as DNA and proteins, which are made of a linear chain of subunits, sugars can link in several places, building branched chains. Complicating matters, while those single-chain macromolecules are usually made by referring to a template, glycans are more free form. A scrum of enzymes, each making its signature modification, determines their final structure. Related Stories
Also in Industry News
A comprehensive analysis of evidence-based information to help manage myopia - News-Medical.Net
Applying AI to map how COVID-19 virus attacks the heart
Abnormal calcium levels in mitochondria may cause neuronal cell death in Alzheimer's disease